Profile · Biotech · Watertown, MA
Vishal Patel
He took two struggling startups, fused them into one, and pointed the result at the enzymes that make skin leak. The bet underneath Triveni Bio: genetics, not guesswork, should pick the drug.
He took two struggling startups, fused them into one, and pointed the result at the enzymes that make skin leak. The bet underneath Triveni Bio: genetics, not guesswork, should pick the drug.
In Sanskrit, Triveni is the meeting point of three rivers. The name is not decoration. Triveni Bio exists because two small companies, Amagma Therapeutics and Modify Therapeutics, flowed into one in 2023, and Vishal Patel was the one holding the map. He emerged as co-founder and CEO of the merged entity, and within a year he had turned a paper merger into a clinical-stage company with more than $200 million in the bank.
Today Triveni works out of a Watertown, Massachusetts life-sciences hub, where it leased the top floor according to a Boston Business Journal report. The work below the windows is unglamorous and exact: antibodies aimed at kallikrein 5 and 7, a pair of skin-barrier enzymes that misbehave in atopic dermatitis. Patel's thesis is that you can read the genetics of a disease first, find the patients whose biology actually matches your drug, and only then spend the years and dollars on a trial. Pick the right fight before you throw the punch.
He says it plainly: "We're building a platform in service of our pipeline." Most biotechs say the reverse, building a shiny platform and hoping a drug falls out. Patel inverts the order on purpose. The programs come first; the technology earns its keep by making the programs better.
We have built a differentiated pipeline of novel drug targets.— Vishal Patel, on the $115M Series B
Most biotech CEOs come up through the lab and stay there. Patel's route was stranger. He started in bioengineering at the University of Illinois, then took a detour through government, working at the U.S. Department of State and the U.S. Senate, where he contributed to drafting the Affordable Care Act. He helped write healthcare policy before he ever ran a healthcare company.
Then he went back to school, hard. A PhD in biological chemistry and molecular pharmacology at Harvard, where he was a National Science Foundation Fellow, and an MBA at MIT. Two of the most demanding institutions in the country, stacked on top of a bioengineering degree and a stint on Capitol Hill.
Industry came next, and in layers: roles of increasing responsibility at Merck KGaA, then Vice President of Strategy and Scientific Engagement at Novartis steering R&D strategy and portfolio decisions, then Head of Portfolio Strategy and Alliances at Flagship Pioneering, the venture creation engine behind Moderna. By the time he sat in a founder's chair, Patel had spent two decades learning how drugs get chosen, funded, killed, and occasionally saved. He had also, somewhere along the way, become a reservist in the U.S. Navy, and he still is.
Triveni's pipeline reads like a thesis about restraint. Rather than chase the crowded targets, Patel's team picks the enzymes and pathways where the genetics point clearly, then designs antibodies to match. Here is what they are building.
A monoclonal antibody blocking kallikrein 5 and 7, the skin-barrier enzymes implicated in atopic dermatitis (eczema). An IND submission was planned for early 2025.
A two-in-one antibody that pairs KLK 5/7 inhibition with IL-13 targeting. Patel calls it "two orthogonal mechanisms of action" in one molecule.
An inhibitor of trypsin 1 and 2 for hereditary pancreatitis, a genetic disorder affecting roughly 10,000 U.S. patients with no approved treatments.
Triveni launched with a $92 million Series A co-led by Atlas Venture and Cormorant Asset Management. Just over a year later, it added a $115 million Series B led by Goldman Sachs Alternatives, with Fidelity and Deep Track Capital joining and every major Series A backer returning. Raising more on the second round, faster, with the same investors doubling down, is the clearest vote of confidence a private biotech can get.
When asked about Triveni's market focus, Patel's answer was characteristically dry: "We've found our sweet spot."
The pitch sounds simple until you watch how rarely the industry follows it. Triveni calls its method "genetics-informed precision medicine." In practice that means starting from human genetic data, reading which mutations and which biology drive a disease, and only then designing an antibody to intervene at exactly that point. The goal is to establish proof-of-concept early, before the money runs deep, by leaning on genetic and mechanistic evidence rather than hope.
Atopic dermatitis is a fitting first target. It is common, miserable, and biologically messy, with a skin barrier that leaks and an immune system that overreacts. Kallikrein 5 and 7 sit at the heart of that barrier dysfunction, which is why Triveni's lead antibody, TRIV-509, goes straight for them. The follow-on, TRIV-573, is more ambitious: a bispecific that hits the kallikreins and IL-13 at once, two separate levers on the same disease pulled by a single molecule. Patel describes the pair of mechanisms as "orthogonal," which is the polite scientific way of saying they fail independently, so combining them raises the odds that something works.
The third program is the one that reveals the philosophy most clearly. Hereditary pancreatitis affects only about 10,000 people in the United States and has no approved treatment. It is not an obvious commercial blockbuster. But the genetics are crisp, the unmet need is total, and the biology rhymes with the rest of the pipeline. Choosing it is a statement: go where the science is clearest, not where the marketing is easiest.
A first-time founder rarely assembles a cap table like this one. Atlas Venture and Cormorant Asset Management co-led the Series A, with OrbiMed, Viking Global Investors, Invus, Polaris Partners, and Alexandria Venture Investments all in the room. The runway from that round alone stretched into 2027. Then Goldman Sachs Alternatives led the Series B, bringing Fidelity Management & Research Company and Deep Track Capital as new names while every major Series A investor re-upped.
Patel did not just take the money. He used the Series B to build out the bench, naming Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer and expanding the company's data-science platform with a focus on precision dermatology. The pattern is consistent with the man: raise on the strength of the programs, then spend on the people and the data that make the programs run.
Atlas Venture & Cormorant Asset Management, with OrbiMed, Viking Global, Invus, Polaris Partners, and Alexandria.
Goldman Sachs Alternatives, joined by Fidelity and Deep Track Capital. All major Series A backers returned.
"We're building a platform in service of our pipeline."
"TRIV-573 uniquely combines two orthogonal mechanisms of action."
"We've found our sweet spot."
While running a venture-backed biotech, Patel keeps a second commitment most CEOs don't: active service in the U.S. Navy Reserve.
Before treating disease, he helped draft the Affordable Care Act on Capitol Hill. Few biotech founders have edited healthcare from the legislative side.
"Triveni" means a confluence of three rivers, a quiet nod to a company born from a merger of separate streams.
Even as CEO, he stayed an Atlas Venture advisor and Entrepreneur in Residence, keeping a view from both sides of the term sheet.
Triveni leased the top floor of a Watertown life-sciences hub, per a BBJ report. The view is the perk; the science is the work.
Illinois for engineering, Harvard for the PhD, MIT for the MBA. He collected the science, the medicine, and the business before betting on himself.
In 2025, Fierce Biotech put Triveni on its "Fierce 15" list, an annual selection of the biotech companies it considers most promising. The timing is the interesting part. Triveni earned the nod while its lead drug was still heading toward its first human trials, before any clinical readout could confirm the thesis. The industry was betting on the approach and the team, not the data, because the data does not exist yet.
That is the tension Patel now lives inside. He has the money, the investors, the validation, and a pipeline built on a coherent idea. What he does not yet have is the thing that matters most in biotech: a drug that works in people. The mission Triveni states is to "redefine standard of care for complex diseases" and to "bring hope to patients by tackling the underlying biology of their disease." Those are easy words to write and brutal ones to earn. The next few years of clinical results will decide whether the genetics-first bet was prescience or just an elegant hypothesis.
For now, Patel keeps doing what the rest of his career trained him to do. Read the biology. Pick the fights worth picking. Build the team. Keep one foot in the venture world and one in the U.S. Navy Reserve. And run a company named after a confluence, hoping the streams he merged carry it somewhere a single one never could.